NTRK3 and cancer: For example, the USFDA approved a TRK inhibitor for adult and paediatric patients with cancers that harbour oncogenic NTRK fusions involving NTRK1, NTRK2 or NTRK3, which are present at low frequencies (commonly <1%) in diverse tumour types36.